Michael Rabbia

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink et al. · JAMA Neurology · 2022 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Robert R. Henry, A. Michael Lincoff, Sunder Mudaliar et al. · The Lancet · 2009 · 204 citations

Medicine, Endocrinology, Pharmacology +17

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

Eriene Youssef, Elizabeth Berry‐Kravis, Christian Czech et al. · Neuropsychopharmacology · 2017 · 127 citations · Full text

Medicine, Neuroscience, Pharmacology +13

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression

Jorge A. Quiroz, Paul Tamburri, Dennis Deptula et al. · JAMA Psychiatry · 2016 · 126 citations · Full text

Medicine, Pharmacotherapy, Psychiatry +17

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

Gonzalo Acuña, Dorothee Foernzler, Diane U. Leong et al. · The Pharmacogenomics Journal · 2002 · 77 citations

Veterinary Medicine, Genetics, Pharmacology +16